TrialThe Lancet. Oncology2016

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Alice T Shaw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.